iScience · 2023 · 14 citations · 40 references
MedicineOphthalmologyVision ScienceGene DeliveryGene TherapyOcular DiseaseAge-related Macular DegenerationAngiogenesisMacular DegenerationMacular DiseaseOcular Gene DeliveryOcular Gene TherapyAnti-vegf Ocular TherapyIntravitreal Anti-vascular Endothelial Growth Factor TherapyMacular NeovascularizationNeovascularizationSafety Of Ocular VectorsToxicity Of Ocular VectorsVascular Endothelial Growth FactorVascular Endothelial Growth Factor Inhibition
Neovascular age-related macular degeneration AMD (nAMD) is characterized by choroidal neovascularization (CNV) and could lead to irreversible blindness. However, anti-vascular endothelial growth factor (VEGF) therapy has limited efficacy. Therefore, we generated a chimpanzee adenoviral vector (AdC68-PFC) containing three genes, pigment endothelial-derived factor (PEDF), soluble fms-like tyrosine kinase-1 (sFlt-1), and soluble forms of CD59 (sCD59), to treat nAMD. The results showed that AdC68-PFC mediated a strong onset of PEDF, sFlt-1, and sCD59 expression both in vivo and in vitro . AdC68-PFC showed preventive and therapeutic effects following intravitreal (IVT) injection in the laser-induced CNV model and very low-density lipoprotein receptor-deficient ( Vldlr −/− ) mouse model. In vitro assessment indicated that AdC68-PFC had a strong inhibitory effect on endothelial cells. Importantly, the safety test showed no evidence of in vivo toxicity of adenovirus in murine eyes. Our findings suggest that AdC68-PFC may be a long-acting and safe gene therapy vector for future nAMD treatments.
40
Circulating Angiogenic Factors and the Risk of Preeclampsia
Richard J. Levine, Cong Qian, Lucinda J. England et al. · New England Journal of Medicine · 2004 · 3.6K citations · Full text
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Soraya Rofagha, Robert B. Bhisitkul, David S. Boyer et al. · Ophthalmology · 2013 · 1K citations
Medicine, Pharmacology, Surgery +2